Gene therapy medication, Spinraza can treat the most severe form of neuromuscular disease, spinal muscular atrophy (SMA) that is mostly seen in children from 6 to 18 months of age, finds a new study. The findings of the study are published in the journal New England Journal of Medicine (NEJM).
"The effects are convincing, and this reinforces results from the earlier study," says Mar Tulinius, professor of pediatrics at Sahlgrenska Academy and chief medical officer at the Queen Silvia Children's Hospital.
Inborn Errors of Metabolism
Inborn errors of metabolism are genetic disorders that hamper the body's metabolism resulting in severe clinical manifestations.
Advertisement
‘Spinraza, the drug with nusinersen can alter inherited genetic error condition in children.’
Tweet it Now
In the earlier study, published in NEJM in November, Mar Tulinius also was responsible for the Swedish part. Then Spinraza was administered for the most severe form of spinal muscular atrophy, SMA type 1, which afflicts children before they are six months old.
This time the study concerned SMA type 2, in which the illness occurs when children have learned to sit by themselves but have not yet begun to walk. The muscles gradually weaken, the children never stand upright on their legs and ultimately they need respirators to survive.
![Phase 1 Clinical Trial Results of a Gene Therapy for Spinal Muscular Atrophy]( "Phase 1 Clinical Trial Results of a Gene Therapy for Spinal Muscular Atrophy")
The phase 1 clinical trial of AVXS-101, a gene therapy for spinal muscular atrophy type 1 (SMA1) shows promising results
Two out three children in the current study received Spinraza; one out of three received a placebo. And this time, too, it turned out that the drug with the active substance nusinersen, which partly compensates for an inherited genetic error, altered the children's condition.
Their ability to sit up straight, raise their hands, move by rolling around, etc., was improved by an average of four points on the scale used to measure changes in spinal muscular atrophy. At the same time, children in the placebo group regressed an average of 1.9 points on the scale.
"The natural progression is for the children to lose points on this scale. Although there are variations within the group, they are never destined to get better. The fact that strength and mobility increased in those who received the drug is really quite amazing," Mar Tulinius said.
People with spinal muscular atrophy lack a protein that is required for the motor nerve cells in the spinal cord to function. If both parents are carriers, the likelihood that the child will get the disease is 25 percent.
Every year 10 or so children in Sweden are diagnosed with SMA. The two most difficult variations, type 1 and 2, are covered by a recently issued recommendation from the Swedish Council for Novel Therapies (NT-rådet) of Sweden's municipalities and county councils that under certain conditions and strict control, children should be offered treatment with Spinraza.
"Often, they say no, we can't afford it, when it comes to expensive orphan drugs. But this one produces such good results that it is impossible to ignore," says Mar Tulinius.
Source: Eurekalert
Phase 1 Clinical Trial Results of a Gene Therapy for Spinal Muscular Atrophy
The phase 1 clinical trial of AVXS-101, a gene therapy for spinal muscular atrophy type 1 (SMA1) shows promising results
Advertisement
Two out three children in the current study received Spinraza; one out of three received a placebo. And this time, too, it turned out that the drug with the active substance nusinersen, which partly compensates for an inherited genetic error, altered the children's condition.
Their ability to sit up straight, raise their hands, move by rolling around, etc., was improved by an average of four points on the scale used to measure changes in spinal muscular atrophy. At the same time, children in the placebo group regressed an average of 1.9 points on the scale.
"The natural progression is for the children to lose points on this scale. Although there are variations within the group, they are never destined to get better. The fact that strength and mobility increased in those who received the drug is really quite amazing," Mar Tulinius said.
People with spinal muscular atrophy lack a protein that is required for the motor nerve cells in the spinal cord to function. If both parents are carriers, the likelihood that the child will get the disease is 25 percent.
Every year 10 or so children in Sweden are diagnosed with SMA. The two most difficult variations, type 1 and 2, are covered by a recently issued recommendation from the Swedish Council for Novel Therapies (NT-rådet) of Sweden's municipalities and county councils that under certain conditions and strict control, children should be offered treatment with Spinraza.
"Often, they say no, we can't afford it, when it comes to expensive orphan drugs. But this one produces such good results that it is impossible to ignore," says Mar Tulinius.
Source: Eurekalert
Gene Therapy for Deafness Moves a Step Closer
Mutations in the protein, otoferlin, are linked to severe congenital hearing loss, a common type of deafness in which patients can hear almost nothing.
Advertisement
 Gene Therapy to Detect and Destroy HIV Infected CellsBlood-forming stem cells can be modified with a CAR therapy that can safely engraft in the bone marrow. | Advertisement
|
Advertisement
Recommended Reading
Latest Genetics & Stem Cells News
Scientists have developed the first humanized mouse model for a rare hereditary condition.
A recent study discovered that the placenta, rather than only the brain, is crucial in determining the genetic risk of schizophrenia.
FOXI3 gene was found to be involved in Goldenhar syndrome, one form of developmental disorder, revealed research.
Contrary to previous beliefs, genes may not be fixed and can be influenced by environmental factors and lifestyle choices, according to modern scientific research.
Gene therapy successfully tested on dogs with inherited eye disease is now poised for clinical use in humans.